汤原算命哪个准白河哪里算命的比较好,水城哪里有算命的师傅,临海哪有算命的,南昌哪里有算卦准的高人,温州哪里有算命算的准的地方,烟台附近那个大师灵验,汉源哪个地方算命准

LOS ANGELES, March 2 (Xinhua) -- Those who take a nap are more likely to have lower levels of blood pressure despite stress, said a new study in the latest issue of International Journal of Behavioral Medicine available on Wednesday.In the study, researchers at Sarah Conklin of Allegheny College in Meadville, Pennsylvania examined 85 healthy university students, who were divided into two groups, with one group taking an hour- long nap during the day, and the other group having no time to sleep. Both groups were given a mental stress test.The study found that participants in both groups experienced increase in blood pressure and pulse rates when they took the stress test, but the average blood pressure of those who slept for at least 45 minutes was significantly lower after the stress test than it was for those who did not sleep.The researchers drew the conclusion that a daytime nap of at least 45 minutes may help stressed-out people lower their blood pressure and protect their heart."Our findings suggest that daytime sleep may offer cardiovascular benefit by accelerating cardiovascular recovery following mental stressors," the researchers said in the study."Further research is needed to explore the mechanism by which daytime sleep is linked with cardiovascular health and to evaluate daytime sleep as a recuperative and protective practice, especially for individuals with known cardiovascular disease risk and those with suboptimal sleep quality," they added.Sleep deficiency is common in the United States, posing a long- term health threat. On average, Americans get nearly two hours less sleep a night than they did 50 years ago, according to background information provided by the journal.

BEIJING, March 8 (Xinhuanet) -- U.S. Food and Drug Administration (FDA) announced there was no new reason for safety concern in Pfizer Inc's Prevenar and Sanofi Aventis SA's ActHIBor vaccines, according to media reports Tuesday.Health agencies "have not detected new safety concerns or unusual reporting patterns" in the vaccines, which are used to prevent forms of meningitis and pneumonia, FDA spokeswoman Shelly Burgess said in an emailed statement.Health agencies in the United States will continue to monitor the vaccines for safety, the spokeswoman added.The Japanese health ministry had decided to suspend the vaccines after four unexplained deaths were reported. The causes of the deaths are still investigated, the Japanese ministry said in a release on its website.

SAN FRANCISCO, April 7 (Xinhua) -- Google's Android will become the most popular smartphone operating system worldwide and will account for 49 percent of the market by 2012, IT research and advisory firm Gartner said Thursday.According to Gartner's projections, worldwide smartphone sales will reach 468 million units in 2011, a 57.7 percent increase from 2010.The company predicts that Apple's iOS will remain the second biggest platform worldwide through 2014 although its share will decrease slightly after 2011, on the assumption that "Apple will be interested in maintaining margins rather than pursuing market share by changing its pricing strategy."Microsoft's Windows, driven by its partnership with Nokia, is expected to move into the mid-tier by the end of 2012 and become the third largest in the worldwide ranking by 2013.Some analysts raised doubts on Gartner's forecasts, saying that its assumption on Apple's price strategy contradicts statements by Apple's chief operating officer Tim Cook and the cooperation between Nokia and Microsoft will not have that much of an impact on smartphone market share by 2012.

JAKARTA, April 27 (Xinhua) -- Marine scientists will begin conducting an ecological survey in eight locations throughout the resort island in Indonesia's Bali province that could be developed as marine managed areas due to their biodiversity and coral structure, the Jakarta Post quoted an expert as saying on Wednesday.The survey, which will take place from April 29 to May 11, will be carried out by four international scientists and local scientists from universities.Ketut Sarjana Putra, the marine program director with Conservation International Indonesia, said Tuesday the survey was aimed at identifying marine species and their population in each of the eight locations.Selected from 25 potential marine conservation zones, the eight locations are Pulaki and Pemuteran, Lovina, Les Village, Tulamben and Amed, Padangbai, Nusa Penida, Bukit Uluwatu Peninsula and Perancak Beach. "We will go around Bali, starting from Sanur in the south, heading east, then covering the northern and the western areas, then back to the south," Ketut told the daily.The survey is part of a process to build a network of marine protected areas to effectively manage the island's marine and coastal resources to sustain environmental and socioeconomic value and benefits, with priority given to the eight locations.

BRUSSELS, April 29 (Xinhua) -- As a 2004 European Union (EU) directive on herbal medicine is to be fully implemented on May 1, herbal medicinal products without a license will no longer be allowed in the EU market, the European Commission said in a press release Friday.The Traditional Herbal Medicinal Products Directive, adopted by the EU member states in 2004, introduced a so-called simplified registration procedure with a seven-year transition period for traditional herbal medicinal products to obtain a medicine license.As the transition period is to expire on Saturday, herbal medicinal products from home and abroad, most of which have been sold as food supplements for decades, need to be medically registered or authorized by EU governments in order to remain in the market after May 1.Instead of going through safety tests and clinical trials as regular chemical drugs, applicants are required by the directive to provide documents showing the herbal medicinal product is not harmful in the specified condition of use, as well as evidence that the product at least has a 30-year history of safe use, including 15 years in the EU.However, a wide range of eligibility and technical challenges along with prohibitive costs have so far prevented both local and outside herbal medicinal products from being granted the license.Only a small proportion of indigenous herbal medicinal products have been approved for registration while not a single Chinese or Indian traditional herbal medicinal products have been licensed.Lack of pan-European rules, EU member states had adopted different approaches to herbal medicine, thus creating a "state of anarchy" in the markets despite the fact that indigenous herbs had a 700-year history of use in Europe.Although the directive was intended to harmonize rules of member states and build a level-playing field across the EU, critics argued that the directive may fall short of the aim and create more chaos and uncertainties for the industry.DRAWBACKSThe directive has been under attack for being neither "adequate " nor "appropriate" due to its high registration cost for a single product and its lack of consideration about the Chinese and Indian traditional herbal medicine.Chris Dhaenens, a licensed herbalist in Belgium and a shareholder of a medium-sized herbal importing company doing business with China and ten European countries, said the directive was only appropriate for companies carrying a few products and who could afford the registration costs."It is simply inaccessible to most players distributing high- quality Chinese or Indian herbal products in Europe," he said, adding that the registration fee for a single product could be as high as 150,000 euros.The Alliance for Natural Health, a British-based group representing herbal practitioners, estimated the cost of obtaining a license at between 80,000 and 120,000 pounds (90,000 to 135,000 U.S. dollars) per herb.Dhaenens, who is also the president of the European Benefyt Foundation, a leading traditional medicine group in Europe, argued that the directive only tried to regulate herbal products instead of its practitioners and the whole herbal system, as well as fell short to take the Chinese and Indian traditional medicine into full consideration.Even the European Commission had admitted that the directive was not fit for the registration of Chinese and Indian medicine in an earlier exchange with the European Medicine Agency in Dec. 2008, Dhaenens revealed in an exclusive interview with Xinhua."But they had no money or time to work out an alternative, and so it was left to the member states," he said.